Drugs / Ad/PNP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03754933 | Feb 2019 → Dec 2023 | head and neck squamous cell carcinoma | GeoVax, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-08 | GeoVax, Inc. | Results GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin® in Recurrent Head & Neck Cancer geovax.com ↗
Three of eight patients (37.5%) in this cohort of patients with end-stage disease achieved stable disease. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-08 | GeoVax, Inc. | GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin® in Recurrent Head & Neck Cancer geovax.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad/PNP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03754933 ↗ |
| Route | Other | “Ad/PNP will be injected intratumorally twice on Day 1” NCT03754933 ↗ |